Abstract
Objectives assessment of adherence to treatment in elderly patients with nonvalvular atrial fibrillation who were prescribed anticoagulant therapy with vitamin K antagonist, warfarin, and a new oral anticoagulant rivaroxaban.
 Material and methods. During the study, 322 patients with atrial fibrillation of nonvalvular etiology were observed. Depending on the type of anticoagulant taken, the patients were divided into 2 groups: the first group included 253 (78.6%) people who took warfarin, the second group 69 (21.4%) people, who were prescribed a new oral anticoagulant rivaroxaban.
 Results. By the end of the one-year follow-up from the start of anticoagulant treatment, only 8.7% of patients in the first group followed the doctor's prescription; the second group had 59.4% of adherent patients. The vast majority of patients refused warfarin therapy due to the inability to control INR. In the case of the appointment of rivaroxaban, the reason for the refusal to take was the high cost of the drugs.
 Conclusion. Effective prevention of thromboembolic complications in atrial fibrillation requires the development of appropriate measures to improve adherence to treatment.
Highlights
Цель – оценить приверженности пациентов пожилого возраста с фибрилляцией предсердий неклапанной этиологии, которые находились на антикоагулянтной терапии антагонистами витамина К – варфарином и новым оральным антикоагулянтом – ривароксабаном
Depending on the type of anticoagulant taken, the patients were divided into 2 groups: the first group included 253 (78.6%) people who took warfarin, the second group – 69 (21.4%) people, who were prescribed a new oral anticoagulant – rivaroxaban
Effective prevention of thromboembolic complications in atrial fibrillation requires the development of appropriate measures to improve adherence to treatment
Summary
Цель – оценить приверженности пациентов пожилого возраста с фибрилляцией предсердий неклапанной этиологии, которые находились на антикоагулянтной терапии антагонистами витамина К – варфарином и новым оральным антикоагулянтом – ривароксабаном. В ходе исследования провели наблюдение за 322 пациентами с фибрилляцией предсердий неклапапнной этиологии. Ключевые слова: гериатрия, пожилые люди, фибрилляция предсердий, антикоагулянтная терапия, варфарин. Проблемы приверженности к лечению пероральными антикоагулянтами у пожилых пациентов с фибрилляцией предсердий в Кыргызской Республике. ФП – фибрилляция предсердий; ТЭО – тромбоэмболическое осложнение; АВК – антагонист витамина К; ПОАК – прямой оральный антикоагулянт; АГ – артериальная гипертензия; ИМ – инфаркт миокарда; ИБС – ишемическая болезнь сердца; ХБП – хроническая болезнь почек; СД – сахарный диабет; ТИА – транзиторная ишемическая атака; МНО – международное нормализованное отношение; НОАК – новый оральный антикоагулянт. Рукопись получена: 12.04.2021 Рецензия получена: 02.08.2021 Решение о публикации принято: 24.09.2021
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
